Abstract: A method of identifying a gene or genomic mutation that is linked to causality of a neuropsychiatric disorder is provided. The method comprises identifying exons which exhibit an expression level that is at least within the 75th percentile of exon expression levels within a nucleic acid-containing sample from a mammal having a neuropsychiatric disorder; comparing the sequence of each identified exon to the sequence of a corresponding exon from a healthy control to identify rare or de novo sequence mutations within the identified exon; calculating the burden of rare or de novo mutations within the exon; and determining the correlation between expression level of the identified exon and burden of de novo or rare mutations in the exon, wherein an inverse correlation indicates that the exon gene is linked to causality of the neuropsychiatric disorder.

Abstract: A method of identifying a gene or genomic mutation that is linked to causality of a neuropsychiatric disorder is provided. The method comprises identifying exons which exhibit an expression level that is at least within the 75th percentile of exon expression levels within a nucleic acid-containing sample from a mammal having a neuropsychiatric disorder; comparing the sequence of each identified exon to the sequence of a corresponding exon from a healthy control to identify rare or de novo sequence mutations within the identified exon; calculating the burden of rare or de novo mutations within the exon; and determining the correlation between expression level of the identified exon and burden of de novo or rare mutations in the exon, wherein an inverse correlation indicates that the exon gene is linked to causality of the neuropsychiatric disorder.

Abstract: Methods, apparatus, systems and articles of manufacture are disclosed to manage care pathways and associated resources. An example apparatus includes a system monitor to coordinate a patient data analyzer and a care pathway processor to at least: identify a first patient record associated with a first care pathway; and identify a second patient record that is not on the first care pathway but should be on the first care pathway. The example apparatus includes a graphical user interface including information regarding, in a first area, the first patient record associated with the first care pathway and, in a second area, the second patient record that should be associated with the first care pathway.

Abstract: Methods, apparatus, systems and articles of manufacture are disclosed to manage care pathways and associated resources. An example apparatus includes a system monitor to coordinate a patient data analyzer and a care pathway processor to at least: identify a first patient record associated with a first care pathway; and identify a second patient record that is not on the first care pathway but should be on the first care pathway. The example apparatus includes a graphical user interface including information regarding, in a first area, the first patient record associated with the first care pathway and, in a second area, the second patient record that should be associated with the first care pathway.

Abstract: Methods, apparatus, systems and articles of manufacture are disclosed to manage care pathways and associated resources. An example apparatus includes a system monitor to coordinate a patient data analyzer and a care pathway processor to at least: identify a first patient record associated with a first care pathway; and identify a second patient record that is not on the first care pathway but should be on the first care pathway. The example apparatus includes a graphical user interface including information regarding, in a first area, the first patient record associated with the first care pathway and, in a second area, the second patient record that should be associated with the first care pathway.

Abstract: A method of identifying a gene or genomic mutation that is linked to causality of a neuropsychiatric disorder is provided. The method comprises identifying exons which exhibit an expression level that is at least within the 75th percentile of exon expression levels within a nucleic acid-containing sample from a mammal having a neuropsychiatric disorder; comparing the sequence of each identified exon to the sequence of a corresponding exon from a healthy control to identify rare or de novo sequence mutations within the identified exon; calculating the burden of rare or de novo mutations within the exon; and determining the correlation between expression level of the identified exon and burden of de novo or rare mutations in the exon, wherein an inverse correlation indicates that the exon gene is linked to causality of the neuropsychiatric disorder.

Abstract: The disclosure relates to the genome-wide identification of “rearrangement hotspots”. The disclosure also relates to a microarray chip system for use in detecting genomic rearrangements and a method of manufacturing a microarray chip system useful for detecting genomic rearrangements. The disclosure also relates to methods for detecting genomic rearrangements associated with genetic diseases. The disclosure further relates to methods for using copy number variants in chromosome 2 for detecting Tourette Syndrome.

Abstract: The present invention relates to substituted 3,3-diphenyl-1,3-dihydro-indol-2-one compounds, and the use of such compounds for the preparation of a medicament for the treatment of cancer in a mammal. It is postulated that treatment of cancers is achieved in which inhibition of protein synthesis and/or inhibition of activation of the mTOR pathway is an effective method for reducing cell growth. Examples of such cancers are breast cancer, renal cancer, multiple myeloma, leukemia, glia blastoma, rhabdomyosarcoma, prostate, soft tissue sarcoma, colorectal sarcoma, gastric carcinoma, head and neck squamous cell carcinoma, uterine, cervical, melanoma, lymphoma, and pancreatic cancer. A particular subclass of compounds are represented by the formula (II) wherein at least one of X1 and X2 is a heteroatom substituent, e.g. 6-chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one.